New chikungunya vaccine shows promise in early trial
NCT ID NCT06669208
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an inactivated chikungunya virus vaccine called HydroVax-005 CHIKV in 48 healthy adults aged 18 to 49. Participants received two doses of either a low or high dose of the vaccine or a placebo. The main goal was to check safety and how well the vaccine triggers an immune response. Results will help decide if larger studies are warranted.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HydroVax-005 CHIKV vaccine (inactivated chikungunya virus)
What this could lead to
If successful, this could lead to a safe and effective vaccine to prevent chikungunya fever, a painful mosquito-borne disease.
What could go wrong
This is an early Phase 1 trial with only 48 participants, so results may not apply to larger populations. The vaccine may not produce strong enough immunity or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHIKUNGUNYA FEVER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke University Health System
Durham, North Carolina, 27705, United States